IQVIA and Veeva Systems has announced an expansion of their partnership with the selection of Veeva CTMS, eTMF, Study Startup, and Site Connect as enterprise standard applications that will be used across IQVIA clinical development studies.
Lonza and Qurient, a clinical-stage biopharmaceutical company, has announced an exclusive license agreement for the use of Qurient’s cyclin-dependent kinase 7 (CDK7) inhibitors for dual-payload antibody-drug conjugate (ADC) applications.
Drew Hope, PhD, BSc (Hons), MRSB, GMP compliance consultant and UK qualified person at eXmoor Pharma, looks at what manufacturers should expect from a contract QP.
Vantage Nutrition, an ACG group company, will use SupplySide Global to highlight the evolving role of the nutraceutical CDMO in helping brands create differentiated, efficacious products that meet changing consumer demands.
Azenta Life Sciences announce the CryoArc Vita-76, a high-efficiency cryogenic storage system design optimised for In vitro fertilisation (IVF) clinics and reproductive medicine facilities.
Pharmaceutical manufacturers face constant pressure to increase productivity while maintaining the quality, consistency and traceability demanded in highly regulated production environments. Beth Ragdale, Beckhoff UK & Ireland, discusses.
Antibody-drug conjugates (ADCs) have transformed oncology therapeutics by combining the selectivity of monoclonal antibodies with the potency of highly cytotoxic small-molecule drugs. Rongrong Li, senior principal scientist, WuXi AppTec discusses.
The ASLS Korea 2026 Autumn Congress will bring together healthcare professionals, researchers and industry experts from around the world for two days of scientific exchange and clinical education on 7-8th November at COEX, Seoul.
Based on conversations with more than 40 pharmaceutical manufacturing leaders across Europe, ManuPharma's latest research explores the practical challenges facing the industry. Lina Elcheik, conference director, ManuPharma discusses.
Upperton has unveiled a new brand identity at CPHI Milan, marking a milestone in the company's evolution into an end-to-end CDMO focused on solving the challenges of molecule development across oral, nasal, pulmonary and parenteral dosage forms.
